Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

3 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 3

3(50.0%)

Phase 2

2(33.3%)

N/A

1(16.7%)

6Total

Phase 3(3)

Phase 2(2)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT05943457Not ApplicableRecruiting

Vitamin K2 Supplementation in Adult Episodic Migraine

Role: collaborator

NCT03305536Phase 2Unknown

Decalcification of the Aortic Valve by Vitamin K2 (Menaquinone-7)

Role: collaborator

NCT02517580Phase 2Completed

Vitamin K2 Supplementation and Arterial Stiffness in the Renal Transplant Population (The KING Trial)

Role: collaborator

NCT01287182Phase 3Completed

Trial of Ateronon in Patients With Coronary Disease to Evaluate Its Effectiveness in Assessing the Risk Factors of Atherosclerosis

Role: lead

NCT01272986Phase 3Completed

Trial of Screening for ALOA-IgG AtheroAbzyme Test

Role: lead

NCT01286909Phase 3Unknown

Efficacy of Laflavon in Lowering Triglycerides and Raising High-Density Lipoprotein (HDL)

Role: lead

All 6 trials loaded